Chemistry: analytical and immunological testing – Heterocyclic carbon compound – Hetero-o
Reexamination Certificate
2004-11-03
2008-12-16
Wallenhorst, Maureen M (Department: 1797)
Chemistry: analytical and immunological testing
Heterocyclic carbon compound
Hetero-o
C436S063000, C436S161000, C436S173000, C436S901000
Reexamination Certificate
active
07465586
ABSTRACT:
A method for confirming the active intake of marijuana and its active component Δ9-tetrahydrocannabinol (“Δ9-THC”) by detecting the amount of 11-nor-Δ9-THC carboxylic acid (“THCA”) in oral fluid at the picogram per milliliter (pg/ml) level using chromatography/mass spectrometry/mass spectrometry (“GC/MS/MS”).
REFERENCES:
patent: 4921788 (1990-05-01), Deutsch
patent: 5264373 (1993-11-01), Wang et al.
patent: 5292899 (1994-03-01), Tius et al.
patent: 5302703 (1994-04-01), Buechler et al.
patent: 5324642 (1994-06-01), Baumgartner
patent: 5326708 (1994-07-01), Lewis
patent: 5466579 (1995-11-01), Baumgartner
patent: 5532131 (1996-07-01), Lewis
patent: 5595653 (1997-01-01), Good et al.
patent: 5817766 (1998-10-01), Hui et al.
patent: 6022693 (2000-02-01), Baumgartner
patent: 6063637 (2000-05-01), Arnold et al.
patent: 6248598 (2001-06-01), Bogema
patent: 6309827 (2001-10-01), Goldstein et al.
patent: 6350582 (2002-02-01), Baumgartner
patent: 6582924 (2003-06-01), Baumgartner
patent: 6686209 (2004-02-01), Wang et al.
patent: 6702988 (2004-03-01), Sagona et al.
patent: 2002/0115089 (2002-08-01), Goldstein et al.
patent: 2002/0142484 (2002-10-01), Wang et al.
Brandt et al. (Abstract) Determination of 11-Nor-DELTA9-tetrahydrocannabinol-9-carboxylic acid in urine by use of HPTLC-UV/FTIR On-Line Coupling. Journal of Planar Chromatography-Modern TLC, vol. 10, No. 5, Sep.-Oct. 1997, pp. 348-352.
Chiarotti et al., “Analysis of 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in biological samples by gas chromatography tandem mass spectrometry (GC/MS-MS)”, Forensic Sci Int. Oct. 9, 2000; 114 (1): 1-6.
Cone et al., “Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol”, J. Anal. Toxicol. May-Jun. 1987; 11(3): 89-96 (abstract only).
Cone et al., “Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations”, J Anal Toxicol. Nov.-Dec. 2002; 26 (8): 541-6 (abstract only).
Gustafson et al., “Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans”, Clin Chem. Jul. 2003; 49(7): 1114-24 (abstract only).
Gustafson et al., “Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydroannabinol administration”, J Anal Toxicol. Apr. 2004; 28(3): 160-7 (abstract only).
Kintz et al., “Pharmacological criteria to use alternative specimens for DUI controls”, available at www.icadts.org/proceedings/show.php?paper=2000-167.pdf.
Kintz et al., “Testing human hair for cannabis. II. Identification of THC-COOH by GC-MS-NCI as a unique proof”, J Forensic Sci. Jul. 1995; 40 (4): 619-22 (abstract only).
Liang et al., “A rapid instrumented fluorescence immunoassay for the detection of tetrahydrocannabinols”, available at www.w.se/trat—sau/+2000/Poster10.pdf.
Lindgren et al., “Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis”, Psychopharmacology (Berl). 1981; 74(3):208-12 (abstract only).
Lyons et al., “A comparison of Roche Kinetic Interaction of Microparticles in Solution (KIMS) assay for cannabinoids and GC-MS Analysis for 11-nor-9-carboxy-delta9-tetrahydrocannabinol”, J Anal Toxicol. Oct. 2001; 25 (7): 559-64 (abstract only).
Niedbala et al., “Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana”, J Anal Toxicol. Jul.-Aug. 2001; 25 (5): 289-303 (abstract only).
Package Insert for the AMP/MAMP/COC/OPI/THC/PCP Test for Oral Fluids, “Oral Fluid Drug Screen Device”, Oct. 4, 2003, available at www.testcountry.com/iScreenOralInsert.pdf.
Peat, “A brief introduction to oral fluid drug testing”, paper Mar. 27, 2000 http://www.4intercept.com/clinicals/test—results.html.
Perez-Reyes et al., “Passive inhalation of marihuana smoke and urinary excretion of cannabinois”, Clin Pharmacol Ther. Jul. 1983; 34 (1): 36-41 (abstract only).
Schramm et al., “Drugs of abuse in saliva: a review”, J. Anal. Toxicol. Jan.-Feb. 1992; 16(1): 1-9.
Stout et al., “Solid-phase extraction and GC=MS analysis of THC-COOH method optimized for a high-throughput forensic drug-testing laboratory”, J Anal Toxicol. Oct. 2001; 25 (7): 550-4 (abstract only).
Wall et al., “The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man”, J. Clin. Pharmacol. Aug.-Sep. 1981; 21 (8-9 Suppl): 178S-189S (abstract only).
Wall et al., “Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women”, Clin Pharmacol Ther. Sep. 1983; 34(3): 352-63 (abstract only).
Day David
Feldman Michael S.
Kuntz David J.
Foley & Lardner LLP
LabOne, Inc.
Wallenhorst Maureen M
LandOfFree
Oral detection test for cannabinoid use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral detection test for cannabinoid use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral detection test for cannabinoid use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049200